DexCom, Inc.
DXCMDexCom is turning diabetes care into a recurring, data-driven subscription business anchored by sticky medical devices.
Because this is not just a gadget company, it is a long-term shift in how millions manage a chronic disease.
Business Model
Devices plus recurring sensors
It sells wearable transmitters and high-margin disposable sensors that must be replaced regularly.
Economic Engine
High cash generation
Strong gross margins near 60 percent and free cash flow that exceeds reported profit power reinvestment.
Long-Term Lens
Ecosystem durability
The key question is whether DexCom can remain embedded in patient routines and insurer coverage for decades.
BinaPrint Snapshot
Style
Build
Fitness
Strong
Updated Mar 8, 2026
On this page
Company Story
How do DexCom, Inc.'s business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“DexCom is building a high-margin, recurring medical technology platform that could compound for decades if continuous glucose monitoring becomes standard care worldwide.”
What does DexCom, Inc. actually do?
DexCom designs and sells wearable devices that continuously measure glucose levels for people with diabetes.
- Makes small sensors worn on the body that track glucose all day and night
- Sends real-time readings to smartphones and insulin pumps
- Provides software and data tools that help patients and doctors adjust treatment
Why it matters
Chronic condition, daily use
Diabetes requires constant management, which makes continuous monitoring a recurring, everyday need rather than a one-time purchase.
How does DexCom, Inc. make money?
DexCom makes money by selling monitoring systems and the disposable sensors that users must regularly replace.
- Upfront sale of transmitters and receivers
- Ongoing sales of disposable sensors replaced every few days or weeks
- Reimbursement from private insurers and government health programs
Economic clue
60.1 percent gross margin
High gross margins show pricing power and room to fund research, marketing, and global expansion.
Why do long-term investors keep DexCom, Inc. on the radar?
DexCom sits at the intersection of rising global diabetes rates and a technology shift toward real-time health monitoring.
- Revenue has grown about 17.5 percent per year on average over five years
- Earnings per share have grown about 39.8 percent per year on average over five years
- Free cash flow margin is 23.1 percent, showing strong underlying economics
Investor takeaway
Build style, strong fitness
The company reinvests heavily for growth while maintaining solid profitability and cash generation.
Based on company financial statements.
What Could Change The Story
- Proved it would move the profile toward Venture.
- Matured would move the profile toward Vault.
Benchmark Comparison
How has DexCom, Inc. performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$748.19
-25.2% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| DXCM | -25.2% | $748.19 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame DexCom, Inc.
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- Exposure to long-term growth in diabetes care and wearable medical technology
- A company reinvesting profits rather than paying dividends
- A business with strong margins and rising earnings over many years
Be Careful If You Expect
- Stable dividends, since DexCom pays none
- Flat margins, because operating margin at 19.6 percent has been contracting
- Low regulatory risk, as medical devices depend on approvals and insurance coverage
What To Watch Over Time
- Whether gross margin stays near or above 60 percent as competition grows
- Adoption beyond intensive insulin users into broader type 2 diabetes populations
- How much of profit continues converting into free cash flow above net income
BinaPrint Position
Where does DexCom, Inc. sit on the BinaPrint map right now?
Test whether business quality and financial profile match the company's stated narrative.
Advanced BinaPrint details
Open the axes, investor fit, and risk framing behind this profile.
Key Metrics
Which metrics matter most for DexCom, Inc. right now?
Three durable business metrics that matter more than day-to-day price moves.
17.5 percent per year
39.8 percent per year
60.1 percent gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | 17.5 percent per year | Five-year average revenue growth shows steady expansion of the user base and adoption. |
| EPS Growth | 39.8 percent per year | Five-year average earnings per share growth shows profits scaling faster than sales. |
| Margin Quality | 60.1 percent gross margin | High gross margin gives room to invest in research and absorb competitive pressure. |
Based on company financial statements.
Fundamentals
What do DexCom, Inc.'s fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
11.5% ROIC
60.1% gross margin
23.1% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 11.5% ROIC | The business is currently showing fair capital efficiency. |
| Profitability | 60.1% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 23.1% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold DexCom, Inc.?
DexCom, Inc. currently appears in these ETF and fund proxies.
QQQ
Invesco QQQ Trust, Series 1
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about DexCom, Inc.?
Company-specific questions readers often ask about DexCom, Inc..
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
DexCom makes wearable devices that continuously measure blood glucose levels and send the data to smartphones and medical devices.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
Continuous glucose monitoring becomes the global standard of care for both type 1 and a growing share of type 2 diabetes, expanding the addressable market for decades.
Recurring sensor sales create a subscription-like revenue stream tied to a lifelong condition, supporting durable revenue and high gross margins near 60 percent.
Earnings per share have grown about 39.8 percent per year on average over five years, showing operating leverage as scale increases.
Strong cash generation, with free cash flow running at 1.29 times net income, funds research and manufacturing expansion without heavy dilution.
Bear case
What can break
A breakthrough non-invasive glucose monitoring technology could make wearable sensors obsolete, collapsing demand for DexCom's core products.
Aggressive pricing from larger medical device rivals could push gross margin well below 60 percent and permanently reduce profitability.
Changes in insurance reimbursement or government healthcare policy could limit coverage, directly shrinking the addressable market.
If diabetes prevention or cures significantly reduce the patient population over decades, long-term demand growth could slow materially.
Risk Radar
Key Risks
Where downside pressure can build.
Margin pressure: Gross margin is 60.1 percent but operating margin has fallen to 19.6 percent, and sustained compression could cut earnings growth sharply.
Regulatory and reimbursement risk: A large share of revenue depends on insurance and government health programs approving and paying for devices.
Product concentration: The business is heavily centered on continuous glucose monitoring systems and related sensors.
Pressure points
Concentration risk
DexCom is largely focused on continuous glucose monitoring systems and related disposable sensors, making the company dependent on one core product category. If this category faces disruption or reimbursement cuts, there is limited diversification to offset the impact.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $68.10
- Daily move
- -3.66%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.